Rapport Therapeutics (RAPP) Competitors $11.45 +0.39 (+3.53%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. EWTX, IRON, INDV, KNSA, ANIP, IMCR, EVO, VERA, APGE, and MESOShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Edgewise Therapeutics (EWTX), Disc Medicine (IRON), Indivior (INDV), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Immunocore (IMCR), Evotec (EVO), Vera Therapeutics (VERA), Apogee Therapeutics (APGE), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Edgewise Therapeutics Disc Medicine Indivior Kiniksa Pharmaceuticals ANI Pharmaceuticals Immunocore Evotec Vera Therapeutics Apogee Therapeutics Mesoblast Rapport Therapeutics (NASDAQ:RAPP) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Which has preferable valuation and earnings, RAPP or EWTX? Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79M-$13.84-0.83Edgewise TherapeuticsN/AN/A-$100.16M-$1.45-11.31 Does the media prefer RAPP or EWTX? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 4 mentions for Rapport Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.31 beat Rapport Therapeutics' score of 0.73 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RAPP or EWTX? Rapport Therapeutics currently has a consensus target price of $32.67, suggesting a potential upside of 185.30%. Edgewise Therapeutics has a consensus target price of $40.22, suggesting a potential upside of 145.26%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Rapport Therapeutics is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is RAPP or EWTX more profitable? Rapport Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A Edgewise Therapeutics N/A -26.83%-25.67% Does the MarketBeat Community prefer RAPP or EWTX? Edgewise Therapeutics received 37 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rapport Therapeutics an outperform vote while only 72.73% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Edgewise TherapeuticsOutperform Votes4072.73% Underperform Votes1527.27% SummaryRapport Therapeutics beats Edgewise Therapeutics on 7 of the 12 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$417.90M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.837.4422.4418.48Price / SalesN/A242.70394.09103.59Price / CashN/A65.8538.1834.62Price / BookN/A6.516.774.25Net Income-$34.79M$143.21M$3.22B$248.23M7 Day Performance3.15%1.98%1.49%0.89%1 Month Performance19.77%6.89%4.00%3.53%1 Year PerformanceN/A-2.52%16.21%5.08% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics2.4438 of 5 stars$11.45+3.5%$32.67+185.3%N/A$417.90MN/A-0.83N/AEWTXEdgewise Therapeutics3.2347 of 5 stars$15.68+5.7%$40.13+155.9%-8.6%$1.64BN/A-10.4560Upcoming EarningsAnalyst ForecastShort Interest ↑Positive NewsIRONDisc Medicine2.3669 of 5 stars$46.16+1.6%$93.80+103.2%+77.5%$1.60BN/A-11.6030News CoveragePositive NewsINDVIndivior3.3456 of 5 stars$11.57+0.1%$15.00+29.6%-34.5%$1.60B$1.17B-33.061,164Earnings ReportShort Interest ↑Analyst RevisionPositive NewsGap UpKNSAKiniksa Pharmaceuticals2.4816 of 5 stars$21.47+0.5%$37.17+73.1%+44.1%$1.56B$423.24M-153.35220Earnings ReportAnalyst ForecastNews CoverageANIPANI Pharmaceuticals4.3469 of 5 stars$70.75+1.3%$80.13+13.3%+7.3%$1.54B$614.38M-128.64600High Trading VolumeIMCRImmunocore3.0457 of 5 stars$30.61+1.5%$60.90+99.0%-49.1%$1.53B$310.20M-32.22320Upcoming EarningsPositive NewsEVOEvotec1.8525 of 5 stars$4.30+1.9%$5.93+38.0%-19.1%$1.53B$796.97M0.004,200Upcoming EarningsShort Interest ↓Gap DownVERAVera Therapeutics2.9478 of 5 stars$23.41+0.8%$64.67+176.2%-40.9%$1.49BN/A-8.9740News CoveragePositive NewsGap DownAPGEApogee Therapeutics2.2159 of 5 stars$37.79+2.6%$92.17+143.9%-22.0%$1.46BN/A-15.6291Positive NewsGap DownMESOMesoblast1.7712 of 5 stars$11.41-3.5%$18.00+57.8%+72.7%$1.45B$5.67M0.0080Gap Down Related Companies and Tools Related Companies EWTX Competitors IRON Competitors INDV Competitors KNSA Competitors ANIP Competitors IMCR Competitors EVO Competitors VERA Competitors APGE Competitors MESO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPP Stock Free RAPP Stock Alerts